Cipla's Important FDA Approval for Generic Advair Diskus® Marks a Milestone

Cipla Receives FDA Approval for Generic Advair Diskus®

Cipla Limited, a prominent global pharmaceutical company, has recently announced a significant achievement with the U.S. Food and Drug Administration (FDA) granting approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus®. This inhalation powder is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD) and comes in three different strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg.

Advair Diskus® is a widely used combination therapy, and this approval is particularly noteworthy as it is Cipla's first dry powder inhaler (DPI) approved from its U.S. manufacturing network. This milestone emphasizes Cipla's continued expansion and dedication to enhancing complex respiratory capabilities within the United States, where the market for fluticasone propionate and salmeterol inhalation powder is approximately valued at $908 million according to IQVIA.

Achin Gupta, Managing Director and Global CEO of Cipla Limited, expressed pride in this achievement, stating, "At Cipla, we're passionate about respiratory care, given our long-standing expertise. This approval reinforces our commitment to expanding access to complex therapies in the U.S. and highlights our strength in developing and scaling sophisticated inhalation products through integrated capabilities."

The approval stands as a testament to Cipla's vertically integrated platform for inhalation products and showcases the company’s commitment to bolstering U.S. manufacturing capabilities for complex respiratory treatments.

Marc Falkin, CEO of Cipla North America, added, "This approval marks our first dry powder inhaler from our New York facility and reflects our targeted investments in building differentiated inhalation manufacturing capabilities in the U.S. It strengthens our ability to provide reliable, high-quality supply in an important and competitive category."

Established in 1935, Cipla is not only known for its growth in the pharmaceutical sector, but it also focuses on providing high-quality, accessible medications. The company's expertise spans multiple therapeutic areas, including respiratory, antiretroviral, urology, cardiology, anti-infective, and central nervous system segments. With over 46 manufacturing sites globally, Cipla produces 1,500+ products and over 50 dosage forms utilizing cutting-edge technology.

Cipla's standing is noteworthy as it ranks as the third largest pharmaceutical company in India, the second largest in the pharmaceutical prescription market in South Africa, and also recognized in the U.S. generics market. While the company has made tremendous progress, what truly sets Cipla apart is its humanitarian approach to healthcare, driven by a commitment to caring for life. This commitment is evident in its history, including the paradigm-changing introduction of a triple anti-retroviral therapy for HIV/AIDS at less than a dollar a day in Africa in 2001, significantly contributing to the movement for inclusiveness and accessibility in healthcare.

As Cipla looks to the future, the FDA approval for Generic Advair Diskus® signifies a major step towards not only increasing its footprint in the respiratory treatment sector but also in making significant advancements in patient care. With a focus on sustainability, innovation, and partnership, Cipla remains dedicated to improving health outcomes across its key markets while fostering a culture of responsibility and community impact.

For more information about Cipla and their range of products, visit Cipla's website.